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!.  I n t r o d u c t i o n  
Human gene therapy trials have begun, and by early 
reports are a success [1]. The initial clinical trial which 
demonstrated the safety of infusing genetically marked 
lymphocytes into humans was reported in 1990 [2]. This 
paved the way for researchers at the National Insti- 
tutes of Health (NIH) :o begin the first therapeutic 
trials of treating adenosine deaminase deficient pa- 
tients with genetically modified lymphocytes. Like the 
Correspondence to: J.C. Krauss, Internal Medicine, The University 
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Glossary of terms applicable to retrovirus mediated gene transfer: 
helper virus, wild type retrovirus (usually when referring to a packag- 
ing cell line); packaging cell line, cell line that contains the factors in 
trans to provide for efficient packaging of a retroviral vector. Packag- 
ing cell lines have been generated by transfecting parts of the 
retroviral genome into an appropriate host cell type and selecting for 
the generation of viral particles; producer cell line, a packaging cell 
line that has been transfected with a retrovirai vector and selected 
for production of recombinant retrovirus; recombinant retrovirus, 
retrovirus that is able to infect cells but lacks the genes necessary for 
replication; retroviral vector, DNA sequence that encodes for a 
recombinant retrovirus; transduction, use of a replication incbmpe- 
tent retrovirus to genetically modify cells; wild type retrovirus, retro- 
virus that contains a full complement of genes necessary for replica- 
tion. For murine retroviruses: amphotropic host range, infects a 
variety of cell types; ecotropic host range, infects only mt.rine cells; 
xenotropic host range, infects other cell types but not murine cells. 
initially reported marking study, the ongoing therapeu- 
tic trial transduces ex vivo expanded peripheral blood 
lymphocytes of patients. In both studies the lympho- 
cytes were modified by the addition of genetic material 
using recombinant retroviruses as the gene transfer 
substrates. Transduction of peripheral blood lympho- 
cytes is essentially a variation on the theme of genetic 
modification of the hematopoietic stem cell. 
The ability to cure diseases by genetically modifying 
cells holds great promise. The initial successful human 
gene therapy trials have rested on a large amount of 
cell culture modeling and animal experimentation to 
develop the necessary techniques to genetically modify 
human cells. The continued successful application of 
gene therapy will depend on the successful use of gene 
therapy models leading to carefully designed clinical 
trials. While a handful of patients have been treated 
with genetically modified lymphocytes, genetic modifi- 
cation of the hematopoietic stem cell for gene therapy 
is just now entering the clinical realm, and clinical 
trials are set to commence in both Italy and the 
Netherlands [1]. A trial to genetically modify the 
hematopoietic stem cell of patients in the United States 
has been approved by the Recombinant DNA advisory 
committee of the NIH anti is awaiting final Food and 
Drug Administration (FDA) approval [1]. Soon clinical 
protocols for gene therapy of the hematopoietic stem 
cell will be taking place on at least two continents. 
Gene therapy is essentially a modification of cellular 
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therapy. The initial gone therapy protocols have all 
been very dependent on cellular transplantation tech- 
niques. The development of human organ transplanta- 
tion has recently been reviewed [3]. The ability to 
remove part of an organ, grow it in short term culture, 
and implant it into a patient so it correctly functions 
will greatly enhance the versatility of gone transfer 
technologies. While transplantation of single cell sus- 
pensions has long been possible for bone marrow, this 
technology has only recently been developed for pan- 
creas and liver [4]. Many hurdles are still to be over- 
come, including the long term and stable expression of 
the transgene in the engrafted cells and the long term 
safety of the genetically modified cells. Additionally, 
i~ues of both cost and appropriate genetic modifica. 
tions will become increasingly important as the use of 
gone transfer technology becomes more widespread. 
Somatic gone therapy as presently practiced in hu. 
roans is the addition of heterologous genetic inlbrma- 
tion into the somatic cells of a patient to treat disease. 
There are many questions to be answered during the 
early use of this therapeutic modality. First, what con- 
ditions should be considered for gone therapy? As with 
any developing technology, life-threatening diseases for 
which no other cure is available make the most attrac- 
tive diseases to test gone transfer technology. Thus, the 
first safety trials of genetically modified cells were 
carried out in patients whose life expectancy was less 
than ¢0 days due to metastatic melanoma [2]. The first 
disease to be treated with genetically modified cells 
(aden.~sine deaminase deficiency) was one which cura- 
tive therapy is only available to those patients with a 
bone marrow transplantation donor. The currently 
available palliative treatment of en~me replacement 
therapy is extremely costly ( > $100 [Xl[)/pt-yr) and only 
marginally effective in one third of the patients [5]. As 
increasing knowledge of the technology is being devel- 
ol~d, investigators will begin to approach less debilitat- 
ing and life threatening diseases. The diseases eligible 
for treatment will need to be carefully defined by the 
physicians administering the treatment, especially to 
avoid genetically enhancing individuals rather than 
treating diseases. Second, what does the future hold? 
Othe, techniques, such as homologous recombination, 
may offer a significant therapeutic advance over cur- 
rently practiced gone addition therapy. However, this 
technology is at least several years from the clinical 
setting. Additionally, augmentation of cellular function 
may still prove very important for the treatment of 
acquired diseases, 
The si~ctrum of genetic diseases that have been 
amenable to the cellular thet,~py of bone marrow trans- 
plantation should all be theoretically approachable with 
genetically modified autologous hematopoietic cells. 
Most of these disorders will still require the cloning of 
the affected gone. The development of complete go- 
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Fig, I, Rcprcscntation of hcmatopoictic stem cell gone therapy, 
nctic maps of the human gcnomc which is underway 
should facilitate the process of gone therapy. In addi- 
tion, a variety e:" acquired diseases should also be 
treatable with ge~letically altered cells. For example, it 
may become routine to genetically alter the peripheral 
blood stem cells of patients undergoing chemotherapy 
for malignant disease to ameliorate the homatopoietie 
toxicity of the chemotherapy [6]. The genetically modi- 
fied cells could be removed at the completion of the 
chemotherapy by the incorporation of a suicide gone 
such as herpes virus thymidine kinase which can be 
selectively killed in rive by gancyclovir [7]. 
Gone therapy has been extensively reviewed [ 1,8-11]. 
This rrview will focus on the use of recombinant retro- 
viruses to genetically alter the homatopoietic stem cell. 
Most clinical protocols to date have utilized ex vivo 
gone therapy as outlined in Fig. 1. The ex vivo ap- 
proach consists of harvesting the target tissue, geneti- 
cally modifying it, and engrafting it back into the 
patient. For hematopoietic stem cell gone therapy, the 
harvest could either be from peripheral blood stem 
cells obtained through cytophoresis or through autolo- 
gous bone marrow harvest. The target cell, the multi- 
potent hematopoietic stem cell, can be enriched for by 
selecting out CD34 positive cells in a single step purifi- 
cation procedure [12,13]. The harvested and enriched 
cells would then be placed in short term culture, pres- 
timulated with growth factors and exposed to the trans- 
ducing agent. Finally, the genetically modified cells 
would be infused into the patient, who would be condi- 
tioned appropriately with chemotherapy or radiation 
therapy. 
The other major form of gene therapy, in vivo gene 
therapy, is not yet feasible for the hematopoietic stem 
cell. This relates to the rarity of the multipotent 
hematopoietic stem cell in the peripheral blood and 
bone marrow, and the the problems of specifically 
delivering gene transfer substrates to those cells. In 
vivo gene therapy has entered clinical trials for the 
immunotherapy of melanoma [1]. In the melanoma 
clinical trial, liposomes containing a complementary 
DNA (eDNA) for human leukocyte antigen (HLA) B7 
will be injected into the metastatic deposits of 
melanoma cells of patients who do not express the 
HLA-B7 allele. The first patients are just now being 
treated with this therapy, and no early results are 
available. Other target cells which have been proposed 
for in vivo gene therapy include the arterial wall (endo- 
thelial and vascular smooth muscle cells), skeletal and 
cardiac muscle cells, and hepatocytes [14-16]. 
11. Bone marrow transplantation for the treatment of 
genetic diseases 
Bone marrow transplantation has been extensively 
studied. Early attempts used bone marrow as a re- 
placement therapy, either by mouth, intramuscular, or 
intravenously for a variety of disorders of the hemato- 
poietic system [17-20]. The ability to completely repop- 
ulate the hematopoietic system with a single cell sus- 
pension of bone marrow cells after lethal chemo- 
therapy or radiation therapy has proven therapeutically 
useful for both genetic disorders and acquired disor- 
ders. A large number of lethal diseases are now cured 
with bone marrow transplantation. 
The transplantability of the bone marrow stem cell 
wi~s defined by investigators studying the effects of 
r~zdiation toxicity. The original observation was that the 
'bone marrow syndrome' of acute radiation toxicity 
could be alleviated by shielding the spleen from the 
radiation [20]. This lead to a number of investigators 
searching for the factors that were produced by the 
protected spleen that prevented death from acute radi- 
ation toxicity. In 1956 it was demonstrated that the 
protected spleens were providing cells that repopulated 
the animals and provided for the return of hemato- 
poiesis [21]. In these experiments, lethally irradiated 
mice and were injected intravenously with a genetically 
identifiable neonatal spleen cells containing the T6 
chromosomal translocation. After recovery of hemato- 
poiesis, the distinctive T6 translocation was isolated 
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from the metaphase preparations of spleen, thymus, 
and lymph node in the irradiated mice, suggesting the 
infused cells were engrafting and providing the protec- 
tive effect against othe~,ise lethal irradiation. The 
same authors transplanted mice with the bone marrow 
of rats, again showing that both lymphoid and myeloid 
lineages of the animals were being contributed to by 
the rat cells. These experiments demonstrated that 
there was muitipotent hematopoietic stem cells in both 
the neonatal spleen (of mice) and the adult bone 
marrow (of rats) and that these cells could be trans- 
planted and lead to long term, stable re-engraftment. 
Shortly after this report, the existence of such a cell in 
humans was transiently demonstrated by the infusion 
heterologous marrow into patients receiving chemo- 
therapy and radiation therapy for incurable malignan- 
cies, and showing the temporary appearance of donor 
type red blood cells present in the recipients' circula- 
tion [22]. These early studies provided the fundamen- 
tab which has made bone marrow transplantation a 
usefld therapeutic modality. 
It soon became apparent, through both animal and 
clinical studies, that the major obstacle in transplanting 
aliogeneic marrow was the major histocompatability 
system [20,23]. Grafts across histocompatability barri- 
ers result in lethal graft versus host disease. Thus, the 
use of marrow grafting was limited to lethal conditions 
among closely HLA matched siblings. Graft versus host 
disease continues to be a major impediment in the 
transplantation of marrow among less than perfect 
HLA matches. Gene therapy hold promise for expand- 
ing the clinical utility of bone marrow transplant by 
genetically modifying the patients' own cells. 
Two groups reported curing of a patients with ge- 
netic diseases using allogeneic bone marrow transplan- 
tation in 1968. The first group reported on a male 
patient with severe combined immunodeficiency 
(SCID) who was cured by the transplant of HLA and 
mixed lymphocyte culture (MLC) identical marrow from 
his sister [24]. Chromosomal analysis of the recipients 
bone marrow documented engraftment with 7/25 
metaphases being XX. As this patient has SCID, the 
patient did not require conditioning with chemo- 
therapy o1' radiation therapy for successful engraftment 
of his sister's bone marrow. In the same issue of 
Lancet, another group reported the cure of a boy with 
Wiskott-Aidrich syndrome. He required conditioning 
with cyclophosphamide to accept the marrow graft. He 
engrafted with marrow from his HLA identical sister, 
as evidenced by 90% of the metaphases in his marrow 
having his sister's karyotype (XXX) [25]. Thus, the 
stage was set for curing genetic disease with ailogencic 
bone marrow transplantation. 
The use of displacement bone marrow transplanta- 
tion for genetic diseases was reviewed extensively in 
1990 [26]. Thirty diseases in which a primary hemato- 
1% 
poietic defect is present have been cured with bone 
marrow transplantation. For an additional 22 diseases, 
the transplanted hematopoietic stem cells have been 
able to supply a soluble factor and significantly lessen 
the symptoms of the disease. All of these diseases 
theoretically could be treatable with genetically modi- 
fied autologous bone marrow, once the respective genes 
are cloned. Unfo~unately, there are five diseases that 
have not been palliated despite successful engraftment 
of the hematopoietic stem cell. These are GM1 gan- 
gliosidosis (acid-~-galactosidase deficiency), Pompe's 
discase (acid-a-glueosidase deficiency), Nieman Pick 
type A disease (sphingomyelinase deficiency), Krabbe's 
discasc (galactosylceramidase deficiency), and Farber's 
lipogranulomatosis (acid ceramidase deficiency) [26]. 
The failure of ~ n e  marrow transplantation to provide 
therapeutic benefit in Krabbt~'s disease is particularly 
discouraging, because bone marrow transplant in an 
animal model had shown significant improvement in 
survival [27,28]. 
A variety of acquired disorders have been cured by 
bone marrow transplantation [29=31]. They include 
acute lymphocytic leukemia, acute myelogenous 
leukemia, chronic myelogenous leukemia, and aplastic 
anemia. The use of gene transfer technology in these 
diseases will require selective gene introduction into 
the malignant cells or normal cells, or other imagina- 
tive uses of gene transfer. As this technology is less 
well developed, the acquired diseases of the hemato- 
poietic system will not be considered further in this 
review. 
The limiting step in hematopoietic gene transfer is 
efficiency of transferring new genes into hematopoictic 
stem cells, if culture systems are developed whereby 
hematopoietic stem cells can be expanded, then less 
efficient means of gone transfer will become applica- 
ble. ~ n e  transfer techniques can be divided into phys- 
ical methods (for example calcium phosphate transfec- 
tion), cell fusion or microinjection methods, or viral 
methods. As there is not a system yet which can 
~xpand hematopoietic stem cells ex rive, physical and 
micromanipulation methods are too inefficient. The 
majority of reports of gene transfer into the hemato- 
poietic ,~tem cell have utilized recombinant retro- 
viruses, which can efficiently integrate up to 1-20 
copies of genetic information into host cells. 
HL MuriM retroviruses as gene transfer agents 
The Retrovirida,e consist of nucleic acid, protein, 
lipid and carbohydrates [32,34]. A schematic of a retro- 
v i ~  is shown in Fig. 2. The nucleic acid is a linear 
positive singe stranded RNA, approximately 1% of the 
retrovirus by weight. The genome sediments at 60-70S, 
and is composed of two identical subunits, with a 
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Fig. 2. Morphology of a wild type murinc rctrovirus. 
typical euka,~,otic modifications of a 5' methyl cap and 
3' poly(A) tail. in a typical wild type virus, only half of 
the RNA by weight is viral genome, and the remainder 
is 5S and 7S small nuclear RNAs, 18S and 28S riboso- 
mal RNAs, and trace amounts of messenger RNA 
species. There are also small amounts of host DNA. 
Moloney murine leukemia virions contain a proline 
tRNA primer. Retroviruses are about 60% protein by 
weight. The proteins are cleavage products of the the 
three major open reading frames, the group associated 
antigens (GAG), reverse transcriptase/integrase 
(POLl, and envelope (ENV). Retroviruses are 35% 
lipid by weight, all of which is derived from the cell 
membrane. They are 4% carbohydrate by weight, and 
the majority of the carbohydrates are associated with 
envelope proteins. 
Retroviruscs have a characteristic morphology which 
is a spherical enveloped virion (80-100 nm diameter), 
with variable surface projections (8 nm diameter). They 
are grouped into type A, B, C or D, based on their 
electron microscopic appearance. Moloney virus, which 
is used for all gene therap~ ' protocols, is a type C virus. 
Type C viruses have an icosahedral capsid containing a 
ribonucleoprotein complex with a core shell (nucleoid) 
in the center of the virus. 
The discovery of wild type retroviruses dates back to 
experiments done by Peyton Rous the early 1900's. He 
discovered a filterable agent that caused tumors, which 
is known as the Rous sarcoma virus [34]. Despite 
intensive efforts, it was not until Ludwig Gross discov- 
ered a similar agent in 1951 that could cause leukemia 
in newborn mice that mammalian retroviruses that 
caused disease were successfully isolated and passaged 
[35]. The retrovirus that is used for all clinical trials 
currently is the Moloney virus, first characterized as a 
highly leukemagenic virus isolated from sarcoma 37 
[36]. The Molone:, virus causes r cell leukemia in all 









Fig. 3. Genomic structure of a wild type murine retrovirus. 
80% of the animals have involvement of the thymus, 
while 20% have a nonthymic form [37]. The major 
difference from the Gross virus is its NB tropism, 
which means it can replicate in NIH Swiss mice (N) 
and BalbC mice (B). NB tropism is determined by 
nuclcotides in the GAG region, specifically by the p30 
protein [38]. 
The complete sequence of a noninfectious clone of 
the Moloney was published in 1981 [39]. Three years 
later the two nucleotide mutations that rendered it 
noninfective were discovered and an infectious form 
was molecularly cloned [40]. This clone was to be used 
to make the first packaging cells used for human clini- 
cal trials, PA317 [41]. The cloning of this virus provided 
a definitive genomic structure of murine retroviruses, 
which had been postulated through biochemical and 
genetic recombination information. 
Murine leukemia viruses have a characteristic ge- 
nomic structure illustrated in Fig. 3 [39]. There are 
three major genes, GAG (group associated antigen), 
POL(polymerase; reverse transcriptase and integrase), 
and ENV (envelope) (reviewed in Refs. 33, 34). Tran- 
scriptional regulation is accomplished through the 
retroviral long terminal repeats (LTR). A standard 
nomenclature has been developed for the various 
retrovirai proteins [42]. Not all proteins are repre- 
sented in every type of retrovirus. 
Each of the structural proteins is translated as a 
propeptide which is then cleaved into the peptides 
found in mature virions. The GAG sequence is first 
translated as a precursor polypeptide of 65 kilodalton 
(kd) molecular weight. This precursor is then cleaved 
into the following proteins (listed in N-terminus to 
C-terminus order as found in the genome) plS(matrix), 
pl2(major phosphoprotein), p30 (capsid), pl0 (nucleo- 
capsid), and p14 :proteinase). 
The POL gene is translated as a protein of 180 kDa 
molecular mass, consisting of af t ,  sion protein of the 
GAG and POL genes, in infected cells, there is a 
1:10-1 : 100 ratio of the 180 kDa G A G / P O L  protein 
to the 65 kDa GAG protein. Translation of Pr~) 
GAGPOL probably occurs by reading through an am- 
ber stop codon at the end of the GAG sequences, 
Approximately one half of the POL protein is directly 
responsible for the reverse transcriptase function, while 
the other half of the raolecule functions as an inte- 
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Fig. 4. Wild type retrovirus life cycle. (l) Attachment of the retrovirus to a specific receptor through interactions with its the relroviral envelope 
proteins; (2) internalization of the retrovirus; (3) disruption of viral RNA and reverse transcriptase/integrase complex iJllo the cytoplasm; (4) 
reverse transcription of single stranded (ss)RNA to ssDNA, and then second strand DNA synthesis to form a double stranded circular 
intermediate; (5) transportation of the double smmded DNA to the nucleus; (6) integration of proviral DNA into the host cells genomic DNA at 
sites without apparent sequence homology; (7) transcription of the provirus; splicing to subgenomic and genomic RNA forms; (8) assemble of the 
retrovirus at the cell membrane; (9) budding of the retrovJrus from the cell. 
grase. There are 20-70 copies of POL per virion, and 
at least one molecule of POL is tightly associated with 
the genomic RNA. 
The final gene is envelope (ENV). Envelope is 
translated from a spliced messenger RNA as a precur- 
~ r  of 8(1 kDa molecular mass. This precursor protein 
is then cleaved into gp70 and gpl5. Gp70 is the major 
envelope structural prt~tein. ~ o n g  different retroviral 
i~lates it is highly polymorphic. This protein deter- 
mines the host range of the retrovirus, plSE functions 
as the gp70 anchor and is also known as the transmem- 
brahe protein. 
The long terminal repeats are critical for replica- 
tion, integration, and transcriptional functions of the 
relro Irus. Their genomi¢ structure has been exhaus- 
tively studied, The long terminal repeats are divided 
into three structural region.~ known as US, R and U3. 
The orientation of these elements is the same in the 5' 
and 3' long terminal repeats, The U3 region provides 
for mt~,~t of the transcriptional control. It contains a 
negative acting upstream control region, a enhancer 
region that is duplicated, and a TATA box for the 
initiation of transcription, The R region contains the 
consensus ~quence for polyadenylation. It also is im- 
portant in the transfer of chain synthesis during retro- 
virus replication. The U5 region contains the tRNA 
primer binding site used for initial negative strand 
DNA synthesis. 
The assembly of retroviral particles is a complex 
process that is not yet fully elucidated. As shown 
through electron microscopic studies, it appears that 
the assembly of type C retroviral particles occurs at the 
plasma membrane. Some protein processing also oc- 
curs in the budded retroviral particle, as newly re- 
leased virions are less infectious than older virions, 
The normal retrovirus life cycle is depicted in Fig, 4, 
The following discrete (=vents can be identified. The 
specific events in retro~irus infection and replication 
are attachment to the re~ptor, internalization of the 
retrovirus, synthesis of double stranded DNA in the 
cytoplasm through reverse transcription, transport to 
the nucleus, integration of the DNA into sites without 
apparent sequenc~ homology, production of subge- 
~mic and genomic RNA transcripts, and assembly of 
the virus and budding of the mature virions, For use in 
gone therapy, retroviruses have been genetically modi. 
fled to provide for efficient gone transfer without caus- 
ing the spread of wild type virus in the host animal. 
The modification is to render them replication defec- 
tive by removi~ part of GAG, and all of the POL and 
ENV genes, DNA sequences of interest are then cloned 
into the proviral genome. The replication defective 
vectors are passaged by the use of packaging cell lines, 
which arc described in tee following te~. A glossary of 
terms that arc fr~uently used is provided at the begin- 
ning of the text. 
The earliest use of retroviruses as shuttle vectors 
was in transferring the thymidine kinase gene from 
herpes virus [43,44]. In 1983 investigators used a molec- 
ular hybrid of the Moloney sarcoma virus and the 
Moiom:y leukemia virus in combination with replica- 
tion competent retrovirus to complement the defect in 
hypoxanthine phosphoribosyltransferase (HPRT)defi- 
cient cells lines (mutant HELA cells, SV-40 trans- 
formed fibroblasts, and EBV-transformed lympho- 
blasts) [45]. in 1984 the same group was able to express 
human HPRT in the bone marrow of mice using a 
mixture of wild type retrovirus and the recombinant 
HPRT encoding retrovirus [46]. The mice remained 
viremic, and so it was impossible to conclude whether 
or not the hematopoietic stem cell had been trans- 
duced with the recombinant retrovirus, or whether 
early hematopoietic progenitors were persistently re- 
infected, leading to continued transgene expression. 
The key to bringing retrovirus mediated gone trans- 
f~;~ into the clinical arena was the d~:elopment of 
packaging cell lines that could produce high titers of 
replication defective recombinant retrovirus. The ae- 
velopment of packaging call lines depended on several 
important observations. First was the identification of 
the packaging sequence of an avian retrovirus (the 
spleen necrosis virus), in 1982 the sequences between 
nucleotides 100 and 285 from the 5' long terminal 
repeat (LTR) were identified as necessary for the re- 
covery of infectious virus [47]. In 1983 this observation 
was extended to the murine retroviruses, and a murine 
retrovirus packaging cell line was created [48]. Deletion 
of similar sequences as described for the avian retro- 
virus from a Moloney murine retrovirus (a 531 bp 
Ball-Psi I fragment) reduced packaging of the mutant 
genome by at least 100-fold as compared to the wild 
type genome. The mutant genome was stably trans. 
footed into NIH3T3 cells, creating the packaging cell 
line known as ~/',. The packaging cell line ~/'2 was able 
to package a shuttle vector which encoded for a bacte- 
rial drug resistance gone efficiently in the absence of 
detectable levels of wild type virus. Virus produced by 
~P, cells is between 10s-10 ~' colony forming units 
(CFU)/ml, 
Because they encode for a native Moloney ecotropic 
envelope protein ~'2 cells are only able to infect murine 
cells, An amphotropic packaging cell line called ~Pam 
was reported by these same investigators in 1984 [49]. 
The amphotropic packaging cell line was made by 
switching the native ecotropic Moloney envelope provi- 
ral sequence to an amphotropic envelope proviral se- 
quence derived from the virus 4070A. Using this pack- 
aging cell line amphotropic retroviral stocks with titers 
of 104-10 s CFU/ml were generated. This virus has 
titers on human HELA cells as high as murine NIH3T3 
cells, and showed good levels of retrovirus derived 
transcription. However, quantification of retrovirus de- 
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rived protein levels were not made. The successful 
development of an amphotropic packaging cell line 
based just on the envelope sequences of 4070A was in 
distinct contrast to another group's attempt to make a 
packaging cell line derived all from cloned fragments 
of the 4070A virus. The 4070A alone derived packaging 
cell line has almost 100-fold lower titer than ~Pam [50]. 
Although amphotropic cell lines are able to infect a 
wide variety of cell types, they are unable to infect 
Chinese hamster ovary (CHO) cells. 
Like ~2 cells, the Vtam cell line occasionally devel- 
oped helper virus on prolonged passage, or after trans- 
fection with certain types of retroviral vectors. Both the 
a/~ and ~am represented first generation packaging 
cell lines. Probably because the packaging sequence 
deletion does not completely ablate packaging of the 
mutant genome, there is occasional formation of wild 
type virus with these cell lines. This probably occurs 
through the occasional copackag, ing of the mutant 
genomes with the vector genome, and subsequent re- 
combination between the two genomes leading to wild 
type virus formation. 
in 1986, a second generation of packaging cell lines 
was described called PA317 [41]. These packaging cell 
lines had several modifications to reduce the likelihood 
of recombinational events that could lead to wild type 
virus formation. The plasmids used to generate these 
lines were derivatives of the originally sequenced 
Moloney virus which had been corrected at two base 
pairs to become infectious [40,51]. As with the original 
packaging cell lines, the packaging sequences were 
removed from the parental proviral DNA sequences. 
Another modification was the removal of the 3' long 
terminal repeat and replacement with an SV40 
polyadenvlation signal. Stable transfectants of NIH3T3 
cells with this plasmid construct were screened for 
their packaging ability. The best clone (PA317), is able 
to package an N2 based provirus which encodes for a 
mutant dihydrofolate reductase (DHFR) with titers up 
tO 10 7 CFU/ml  without helper virus formation. The 
FDA of the United States has approved PA317 for use 
in several different clinical trials involving human gene 
therapy [ 1]. 
To further reduce the risk of helper virus t'ormation, 
two different sets of third generation packaging cell 
lines were developed. The first described were ~cre  
and qtcrip [52]. They separate the retroviral genome 
into two separate parts, to further reduce the chances 
of recombinational events leading to wild type virus. 
These changes increase the number of recombinational 
events necessary for wild type virus formation from two 
with PA317 to three. The qfcre and ~crip packaging 
cell lines were made from a total of three plasmids, 
with two pla,~mids for each cell line. All three of the 
plasmids have an SV40 polyadenylation signal in place 
of the 3' long terminal repeat. The plasmid that pro- 
vides the GAG and POL proteins is common to both 
cell lines. It is referred to as pcrip-env and it has a 
mutant R21 envelope gene. The ~cre cell line (which 
produces ecotropic virus) contains pA5 mutant 
G A G / P O L  genes and the native Moloney envelope 
sequences, and the "4,'crip cell line (which produces 
amphotropic virus) contains the pA5 mutant G A G /  
POL genes and the 4070A envelope gene. Both of 
these cell line were constructed in a similar manner. 
First the normal G A G / P O L  plasmid was transfected 
into NIH3T3 cells, and the clones were screened for 
reverse transeriptase production. The cell lines that 
produced the most reverse transcriptase activity were 
transfected with the respective ENV plasmids and the 
clones were screened for packaging function. Titers of 
these two packaging cell lines are in the range of 1.10 (' 
CFU/ml,  with a parallel ~k, tiler 2 .10 ~' CFU/ml. Of 
note, the ~kcrip cell line was recently approved for use 
in a human clinical trial for the genetic modification 
fl)r hcpatocytcs in patients with familial hypercholes- 
terolemia [ I1. 
The other third generation packaging cell line pro- 
ducers are known as GP + E86 (an ecotropic packaging 
cell line) and GP + envaml2 (an amphotropic packag- 
ing cell line [53,54]. These packaging cell lines have the 
major advantage that the G A G / P O L  proviral informa- 
tion was put on the same plasmid as a dominant 
selectable marker, and thus selection in hypoxanthine, 
mycolphenolic acid, and xanthine are able to rescue 
G A G / P O L  function from populations of packaging 
cells that have lost their packaging function. These 
investigators utilized Mnloney virus clone 3PO. These 
packaging cells lines have been reported to package N2 
at a titer of 4 .10  t' CFU/mi. 
The development of vectors has been closely tied to 
the development of packaging cell lines, and also to the 
specific experimental aims of the investigators. The 
ideal gene therapy retrovirai vector is safe (does not 
lead to helper virus formation), provides high titcr 
virus (greater than 10 "~ CFU/ml),  and provides for 
high level protein expression in the transduced cell 
population. The safety issue is a relative one. The FDA 
has developed guidelines for recombinant retroviruscs 
for gene therapy that have been published [55,56]. 
Safety from a clinical point of view relates to the 
minimization of chance of exposure to helper virus. 
For clinical virus stocks, this has meant that no replica- 
tion competent virus can bc presem in the ~tocks as 
measured by provirus mobilization assays. In addition. 
the retrovirus stocks also need to be free of other 
potential human pathogens as is required of other all 
other drug products. 
Retrovirus titer is not only related to the specific 
packaging cell line used, but also to the retrovirai 
vector that is being packaged, and to the method used 
to generate the producer cell. A schematic of four 
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different types of retroviral vectors is shown in Fig. 5. 
Early vectors were essentially modifications of replica- 
tion incompetent acutely transforming viruses, with the 
gene of interest placed about 6~-800 base pairs (bp) 
after the 5' end of the proviral sequence. The first 
generation of vectors produced without helper virus 
are typified by pZip [57]. This vector included just 556 
bp of the 5' flanking region, This vector also has 
sequen~s for expression in COS cells (an SV40 origin) 
and for cloning the genomc from transduced cells (a 
pBR322 origin), The eDNA was most efficiently ex- 
pres,,~d from the LTR as compared to the SV~  inter- 
nal promoler, Using this retroviral vector and ~ cells, 
titers of 10 ~ CFU/ml could be generated. 
The s~ond generation of vectors is typified by N2, 
which included more GAG sequences, an! also in- 
cluded the endogenous 3' splice site [58], With this 
~-¢tor liters of 10 ~ CFU/ml could be generated, but 
helper virus formation was observed when used with 
the first generation (~',/~/'am) cell lines. A critical 
~ r v a t i o n  was that the extended GAG ~quence in 
the vector provided for increased packaging of the 
genomie proviral RNA and provided for increased titer 
[59], S~ifically, it was demonstrated that inclusion of 
a portion of GAG increases the titer of the retrovirus 
by 10~100-fold (Moloney murine leukemia virus bases 
~ - 1 0 3 8 ) ,  Also heterologous RNAs were able to be 
efficient~ packaged into retroviral particles when bases 
215-1019 were attached to the RNAs, even in the 
absence of the remainder of the retroviral sequences 
I6ol. 
The first retroviral vectors used in clinical trials is 
the third generation LNL6 vectors [59,61]. This is a 
hybrid vector with a 5' Moloney sarcoma virus genome 
and a 3' Moloney leukemia virus genome. It has been 
further safety modified by site specifically mutating the 
normal GAG start codon from an AT(] to a TAG, 
which in several assays leads to lower wild type virus 
formation. 
The other vector type that was recently approved for 
clinical trials in familial hypercholesterolemia is an 
enhancer deleted vector. This vector has one of the 3' 
LTR internal enhancers (7933 Pvull to 8111 Xbal) 
removed, which greatly decreases LTR transcription in 
transduced cells, but still produces relatively high virus 
titer. Use of this vector with an internal chicken fl-actin 
promoter has been able to achieve a large amount of 
protein expression in a variety of different cell types 
[62,63]. 
A new class of vectors that appears interesting are 
the polycistronic vectors, which utilize sequences from 
picornaviruses to achieve more efficient translation of 
both sequences in a bicistronic messenger RNA [64]. 
Earlier vectors (i.e., pZIPNEO) rely on retrovirus RNA 
splicing in the transduced cells to achieve efficient 
RNA translation. The polyeistronic vectors utilize the 
5' untranslated region of encephelaomyocarditis virus 
(EMCV) to achieve more efficient translation of a 
bicistronic RNA. One of these vectors is able to pro- 
duce two times the NPT activity from a downstream 
location as compared to an SV40 vector. Viruses pro- 
duced with these vectors are of high enough titer to 
potentially be useful as clinical gene transfer agents. 
Retroviral titer is very important for hematopoietic 
stem cell gene transfer. Retroviruses with titer of less 
than l0 s CFU/ml are of very low efficiency in trans- 
ducing the hematopoietic stem cell. The method of 
production of the producer cell line also probably 
influences retrovirus titer. Typically a producer cell 
line is made by transfecting the retrovJral vector into 
the packaging cell line, performing selection, and 
screening clones of the selected cells for the produc- 
tion of virus. Physical means such as calciam phosphate 
precipitation and electroporation will give reasonable 
titer retrovirus by this method, although only 10% of 
the clones screened will produce retrovirus. For vectors 
that do not contain an enhancer deletion, a way of 
increasing the number of virus producing clones is to 
infect a packaging cell line with virus n~ade from a 
packaging cell line of different host range [66]. For 
clinically useful gene therapy stocks, this entails pro- 
ducing virus from the ecotropic packaging cell line and 
using it to cross infect the amphotropic packaging cell 
line. Using this method, most of the screened clones 
will be positive for the production of retrovirus. In 
addition, higher titer virus may be produced more 
rehably. Repetitive cross infection may provide for up 
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to a 10-fold higher titer virus [66]. Some of the highest 
titer virus stocks that have been reported use coceltiva- 
tion of ecotropic and amphotropic stocks to repetitively 
cross infect the opposite cell type [65]. This type of 
maneuver, however, almost always results in helper 
virus formation in the available packaging cell lines. 
Even in cell lines with no homology to the retroviral 
vector being passaged, repetitive cross infection has 
lead to helper virus formation [67]. Thus, other strate- 
gies may need to be developed to generate retrovirus 
stocks of high enough titer to reliably infect hemato- 
poietic cells of primates. 
IV. Transduction of murine hematopoietic stem cells 
The first insertion of genes into the hematopoietic 
stem cells did not utilize retroviruses but rather tradi- 
tional calcium phosphate transfection and selection for 
the introduced gene [68], These experiments were pub- 
lished in 1980. Marrow was harvested from T6T6 mice 
that had been pretreated with vinblastine to increase 
the number of cycling hematopoietic stem cells. The 
genetically identifiable marrow was transfected with 
total cellular DNA from a mouse cell line resistant to 
methotrexate. The transfeeted cells were mixed with an 
equal number of normal bone marrow cells that were 
transfected with normal DNA, and the cell mixture was 
then transfused into lethally irradiated recipient mice. 
The mice were treated with methotrexate during the 
time that they re-initiated hematopoiesis. The investi- 
gators demonstrated an excess of the methotrexate 
resistant treated cells (the T6T6 cells) in marrow of 
mice treated with methotrexate. In addition, they were 
able to protect from toxicity of methotrexate in mice 
that received the transfected bone marrow. They per- 
formed additional experiments to prove that the 
hematopoietic stem cell had been transfected. They 
transplanted 'secondary' mice with the bone marrow 
from their primary recipient mice. The secondary mice 
had a higher percentage of the transfected (T6T6) 
marrow type. The same investigators were able to show 
an increase in dihydrofolate reductase (DHFR) activity 
in the spleens of the transplanted animals. These ex- 
periments opened the door for hematopoietic stem cell 
gene therapy. Using a similar approach, in 1981 the 
same group was able to demonstrate thymidine kinase 
sequences in the marrow of mice [69]. The major 
limitations the calcium phosphate transfection tech- 
nique are the inefficiency of gene transfer and the lack 
of stability of the introduced sequences in the absence 
of ongoing drug selection. 
While replication competent retroviruses had been 
used to express the HPRT gene in mice, the first use of 
a replication incompetent virus to genetically alter bone 
marrow was in 1984 [46,70]. The major advance of 
using retroviruses as the gene transfer substrate was 
the several order of magnitude increased rate of gene 
transfer into murine bone marrow cells. These investi- 
gators were able to obtain transfer of provirus into 
10-25% of colony forming unit spleens (a primitive 
hematopoietic progenitor), at between 0.1-0.25 provi- 
ral copies per cell. This rate of gene transfer was 
observed with both short term cultivations and long 
term (Dexter) culture conditions. Positive spleen 
colonies (which are clonal in nature) showed multiple 
sites of provirai integration, suggesting that it was 
possible to achieve a potentially therapeutic gene 
dosage level. While these experiments did demGnstrate 
adequate provirus levels, transcription of the provirus 
was not demonstrated, nor was provirus derived pro- 
tein in the tissues of the transplanted animals. Addi- 
tionally, assays for provirus in long term (> 4 months) 
animals were not perfon~aed, and provirus levels before 
this time may only reflect early hematopoietic progeni- 
tor infection. 
The first experiments that conclusively demon- 
straled expression of the transgene after helper virus 
free retrovirus gene transfer were published in 1985 
[71]. Using 5-fluorouraeii treated marrow transduced 
with an N2 retrovirus that encoded for neomycin resis- 
tance,neomycin phosphotransferase (NPT) activity was 
demonstrated in the bone marrow of the transplanted 
mice. In addition, a common integration pattern of the 
provirus in all tissues derived from the hematopoietic 
stem cell was shown, suggesting that only a limited 
number (1-5) hematopoietic stem cells were contribut- 
ing to hematopoiesis. They also formed T cell and B 
cell hybridomas from the cells of selected transplanted 
mice to investigate whether any provirus could be 
detected that was not contributing to hematopoiesis. 
By Southern Blot, both the B cell and T cell hybrido- 
mas contained the major proviral integrants observed 
in the tissues of the mice, and a few other integrants. 
This suggests that not all hematopoietic stem cells are 
contributing to lymphopoiesis at any one time. These 
experiments represented a major advance in hemato- 
poietic stem cell gene therapy. However, neomycin 
activity is only a reporter enzyme in this context, and it 
is impossible to determine if therapeutically relevent 
quantities of the recombinant protein were being gen- 
erated in the transduced bone marrow. 
In 1990, the consistent expression of human adeno- 
sine deaminase in mice was achieved with amphotropic 
retroviruses, paving the way for these investigators to 
submit a clinical protocol to transduce the hemato- 
poietic stem cell of patients with ADA deficiency [72], 
In these experiments, human ADA "was expressed in 
mice transplanted with bone marrow transduced with 
amphotropic retroviruses. The vector used for these 
experiments contains a muta;t LTR, which is designed 
to increase protein expression in the cells derived from 
the transduced hematopoietic stem cell. At 34 days, 
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10/10 mice were positive for human ADA activity. In 
this same series of experiments a secondary transplant 
recipient had expression of h-ADA derived from provi- 
ral sequences, The major limitation of these experi- 
ments was that they were only able to show expression 
in ~ %  of peripheral blood lymphocytes and 20% of 
thymocytes. In addition, no data was presented on the 
long term protein expl'ession in the transplanted mice. 
A variety of other genes have been expressed in the 
hematopoietic stem cells of mice using retrovirus medi- 
ated gone transfer [73-77]. Most of these are to model 
a specific disease. One model is of note because of the 
abili~ to study cell specific expression in transplanted 
mice. In 1991 investigators reported on an animal 
model of CDI8 gone replacement therapy [78]. Leuko, 
~te  adhesion deficiency is a rare disca~ cau~d by a 
defective CDI8 gone. Those experiments utilized an 
ecotropic retrovirus, to express human CDI8 for greater 
than 4 months in 40% of a cohort of transplanted mice. 
Cell specific expression of human CDI8 was deter- 
mined in the mice by using monocional antibodies 
directed at both myctoid and lymphoid epitopes 
demonstrating a restriction of transgene expression in 
b~nphoid cells, The restricted lymphoid expression is 
on the basis of decreased tran~ription of the provirus 
in the lymphoid tissues [79]. This type of model is of 
particular use because the cell specific expression of 
the transgene can be exhaustively studied. 
The expression of foreign sequences in the mouse 
has proven to be a powerful model for human gone 
therapy trials, Several hurdles remain to be overcome 
concerning hematopoietic stem cell gone transfer, and 
the murine model should provide a powerful tool to 
perform these experiments, The m~or limitation in all 
experiments to date has been transfer of the genetic 
information into all of the hcmato~ietic stem coils 
that will eventually contribute to hematopoiosis in a 
lethally irradiated animal, Two approaches are cur- 
rontl~t being investigated to overcome this problem. 
The first approach is to bettor understand the biology 
of the hematopoieti¢ stem cell to effeet reliable divi- 
sion of such cells in short term culture. The hemato- 
poietie stem cell of mice was first isolated in 1988, but 
there have been some subsets identified since that time 
[~,81], However, specific protein growth factors that 
reliably lead to an increase in the number of such cells 
have not yet been identified [82], The development of 
a~a~  for primitive hematopoietie stem cells short of 
repopulation of lethally irradiated animals may lead to 
the identification of such protein growth factors. Such 
~'ork is underway in a number of laboratories. Another 
approach is to increase the mutipUeity of infection with 
the retroviral particles. This can either be through the 
partial or complete purification of the hematopoietic 
stem cell, or through increasing the titer of the retro- 
virus [83,84] (and below). Both approaches are being 
actively pursued. A final problem that can be ad~ 
dressed with the murine model is the cell specific 
expression of the transgene in the variety of cells that 
arise from transduced hematopoietic cells. Strategies 
that increase expression such as altering the promoter 
of the provirus are being actively studied. Thus, the 
murine hematopoietic gone therapy model still has 
much to offer, even as clinical trials are beginning for 
human hematopoietic gene therapy. In addition, the 
ability to generate knockout mice by homologous re- 
combination may provide for a number of murine 
animal models of human diseases. 
V. Transduction of canine, feline and primate hemato- 
poletle stem ceils 
Homatopoietic stem cell gone therapy has boon at- 
tempted on larger animals to test the concepts origi- 
nally pioneered in mice. The most extensive experience 
has been with the transduction of canine hcmato- 
poietic stem cell. Dogs offer a particularly useful model 
as they arc an outbred species and several groups have 
extensive bone marrow transplant experience with dogs 
[87]. in addition there is a proven ability to cure 
genetic diseases by performing displacement bone mar- 
row transplantation in dogs [86,87]. 
in 1988 the first experience with transferring genes 
into the hematopoietic stem cell of dogs was reported 
[88]. Six dogs were transplanted with bone marrow 
transduced with two different retroviruses. One virus 
encoded for neomycin resistance and had a titer of 
2.10" CFU/mi, but wvs contaminated with greater 
than l0 -~ helper virus [89]. The other virus encoded for 
a mutant dihydrofolate rcductase (DHFR), had a titer 
of 3.10" CFU/ml, and was helper virus free [89]. In 
addition, an attempt was made to select for transduced 
cells prior to transplant by culturing (preselecting) the 
transduced bone marrow in drug containing media. Six 
dogs were transplanted with transduced bone marrow 
and 4 /6  survived the procedure. Only 1/3 dogs trans- 
planted with proselected bone marrow cells survived, 
while all 3 dogs transplanted with unselected bone 
marrow cells survived. Provirus could not be detected 
by Southern blot in any of the animals, so less than 
2-3% of the hematopoietic progenitors were trans. 
duced. Between 2-5% of the hematopoietic progeni- 
tors were resistant to methotrexate, and the resistant 
percentage could be increased slightly with methotrex- 
ate treatment of the transplanted dogs. Thus, only low 
level gone transfer into the hematopoietic stem cell 
was occurring with these dogs. 
in 1992 another group reported their experience 
with genetically marking the hematopoietic stem cells 
of dogs [90]. Dogs were transplanted with bone marrow 
transduced with helper virus free N2 (nee) virus with a 
titer of 106 CFU/ml. The animals were extensively 
tested and all remained helper virus free for the dura- 
tion of the experiment. In order to increase gene 
transfer efficiency, the marrow was placed into long 
term cultures and transduced with retrovirus 1-3 times 
over a 21 day period. With this regimen up to 85% of 
hematopoietic progenitors from the long term cultures 
became drug resistant, suggesting a high level of gene 
transfer into this cell type. Four dogs were trans- 
planted with marrow conditioning (myeloablative radi- 
ation) and 3 of the 4 dogs survived. In addition, 3 dogs 
were transplanted without marrow conditioning and all 
survived. There was no difference in gene transfer 
rates between the two groups of dogs. Gene transfer 
was assessed by growing hematopoietic progenitors in 
drug selection and then testing the resistant progeni- 
tors for the presence of provirai sequences by the 
polymerase chain reaction. Proviral sequences could be 
demonstrated in no more than 10% of the hemato- 
poietic progenitors at time points of up to one year. 
Additionally, 0.1-1% of T cells were genetically 
marked. Two conclusions can be drawn. First, the 85% 
rate of gene transfer into hematopoietic progenitors 
was not reflective of the hematopoietic stem cell trans- 
duction rate. Second, only low levels of gene transfer 
was achieved into the canine hematopoietic stem cell. 
Thus, more efficient protocols for canine hemato- 
poietic stem cell transduction should be developed. 
In 1992, another group reported their experience 
with genetically modifying the hematopoietic stem cell 
of cats [91]. The retrovirus used was a variant of the N2 
virus and was helper virus contaminated. Four cats 
were transplanted with transduced bon,~ marrow and 
all four survived the bone marrow transplant. Up to 
7% of the hematopoietic progenitor colonies were 
neomycin resistant between 1 and 35 months after 
transplantation. Proviral sequences in tissues of trans- 
planted animals could not be detected with Southern 
blot, so probably less than 5-10% of the cells were 
genetically modified. They were able to detect provirai 
sequences with the polymerase chain reaction in the 
drug resistant hematopoietic progenitor colonies. NPT 
activity was demonstrated in cells derived from one 
animal. None of the cats were viremic with Moloney 
virus, but evidence of helper virus genome was de- 
tected in 2/3  animals tested. Two animals developed 
diabetes with an atypical pancreas histology, but this 
could not be directly related to the presence of the 
replication competent virus. 
Thus, the published experience with gene transfer 
into eats and dogs consistently demonstrates less than 
10% of the hematopoietic stem cells that repopulate an 
animal can be reliably transduced. The same factors 
that prove important for gene transfer in the mouse 
will probably prove to be important in dog and cat 
hematopoietic stem cell gene transfer. These animals 
will provide utility in developing clinical protocols be- 
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cause several authentic animals models exist of human 
diseases in both dogs and cats. 
Gene transfer has been achieved in the hemato- 
poietic stem cells of primates as well. The initial expe- 
rience with primate gene transfer was reported in 1987 
and updated in 1990 [66,92-94]. The initial successful 
report of expressing human adenosine deaminase in 
the hematopoietic cells of primates was reported in 
1987 [92]. Investigators reported on the bone marrow 
transplantation of 6 cynomologous macque (Macaca 
fasicularis) monkeys with bone marrow transduced with 
the SAX vector. This virus expresses both human 
adenosine deaminase and NPT and has a titer of 
6 .10 ~' C F U / m l .  Two methods of transduction of the 
bone marrow were performed. One was cocultivation 
of the bone marrow cells with the retrovirus producer 
cells and the other was transduction with retrovirus 
supernatants. With cocultivation, NPT activity and 
adenosine deaminase (ADA) activities (ADA less than 
0.01% of endogenous) were detected in cells derived 
from the bone marrow. In one animal, investigators 
detected a provirus band at day 66 (of about i / 3  copy). 
With the supernatant infection protocol provirus se- 
quences were undetectable by Southern blot. By in situ 
hybridization, 0.8% of the peripheral blood cells con- 
tained vector specific mRNA sequences. Up to 2% of 
hematopoietic progenitors were drug resistant, and up 
to 8% of clonable T cells were drug resistant. These 
experiments were limited by the fact that they did not 
have access to some of the more recently cloned 
hematopoietic growth factors. 
An update of this work was reported in 1989 [93]. At 
that time a total of 14 monkeys had been lransplanted 
with transduced bone marrow, 10/14 which survived 
the transplant procedure. Six of fourteen animals were 
positive for human ADA activity, at best 0.5% of 
endogenous monkey ADA activity, and none of the 
animals demonstrated long term expression of human 
ADA activity. Only 1/14 animals was positive fi,r 
provirus derived DNA sequences, and that animal was 
only positive at a single time point. Four of fourteen 
monkeys were positive for NPT activity, and none were 
persistently positive for NPT activity. In 1990 another 
summary of this data was reported, stating that of a 
total of 20 monkey transplanted, 2/20 monkeys ex- 
pressed human ADA at 0.2-0.5% of endogenous ADA 
activity, and no human ADA activity was detected past 
90 days [65]. 
In 1990, another group reported their experience 
with transplantation of rhesus monkeys (Macaca mu- 
latta) with bone marrow transduced with neomycin 
encoding retrovirus [65]. The report describes the 
transplantation of 6 monkeys, all of whom survived. 
Three monkeys were transplanted with marrow trans- 
duced with a conventional titer virus, but that had been 
additionally modified to secrete interleukin 3 and inter- 
204 
leukin 6 into the tissue culture media. This retrovirus 
was helper virus free. None of the three monkeys 
transplanted with this marrow were positive for provi- 
ral DNA, despite the use of a sensitive polymerase 
chain reaction method to detect proviral sequences. 
Thus. despite many attempts, only low level or no gene 
transfer into the hematopoietic stem cell of primates 
has been possible using traditional titer retrovirus cell 
lines. 
This same report described the generation of a 
retrovirus packaging cell line of exceptionally high titer 
to overcome the low level gone transfer into primate 
hematopoietic stem cells. This cell line was produced 
by coculturing two different packaging cell lines of 
different host ranges (a repetitive cross infection 
method). The packaging cell line was initially reported 
to have a titer of 10 t° CFU/ml (l(X)0-fold higher than 
any previous report), however, another group reported 
a titer of 4. l0 T CFU/ml for the cell line [66]. in 
addition, this cell line is contaminated with at least 10 "~ 
titer replication competent retrovirus. This packaging 
cell line also continuously secretes interleuKm 3 and 
interleukin 6 into the tissue culture media, 
The first experiments performed with the high titer 
line demonstrated that it could efficiently transduce 
the hematopoietic stem cells of mice [65]. Ten mice 
were transplanted with bone marrow transduced with 
the high titer line and all were positive for provirus at 3 
months after bone marrow transplantation, The trans- 
planted mice demonstrated a reasonable amount of 
provirus in their hematopoietie tissue, estimated to be 
between 0,1=0,3 copies per cell, Having this initial 
encouraging results, three monkeys were transplanted 
with bone marrow transduced with the high titer line 
packaging cell line, All three survived the transplant, 
Remarkably, aU w~r~ positive for prey;tiros derived se. 
quenc~s (by polymerase chain reac~ion~. One animal 
was killed 99 days after bone marrow transplantation, 
and provirus was present in about 1% of hematopoietic 
c~lls, based on semiquantitative polymerase chain reac- 
tion. Thus, it seemed possible that with high enough 
titer virus that the hematopoietic stem cell of primates 
(and perhaps humans) could be transduced, albeit at 
low levels. 
in 1991 an update was provided on both the gone 
transfer efficiency and the safety of this high titer, 
helper virus infected cell line whet, used to transduce 
pr~mat~ bone marrow [95]. Additional rhesus monkeys 
were transplanted with bone marrow transduced with 
the same high tit~r produc~r c¢11 line in the presence 
of autologous bone marrow stromal cells. Prior to 
retrovims transduction, the bone marrow was affinity 
purified on a CD34 column to enrich for hematopoietic 
stem cells. Provirai sequences were detectable in up to 
10% of the peripheral blood T cells, and in one of the 
animals the provirus sequences could be detected by 
Southern blot. Unfortunately, 3 of the 6 transplanted 
animals developed thymic lymphoma. The histology 
was that of a large cell immunoblastic lymphoma, remi- 
niscent of the tumors caused by wild type Moloney 
virus in mice. The monkeys were also shown to be 
persistently viremic with Moloney virus. Southern blot 
analysis of the thymic tumors demonstrated multiple 
copies of the provirus in the tissue, implicating the 
replication of infectious retrovirus within the animals. 
The thymus also was positive for retrovirus derived 
envelope protein, This essentially recapitulated 
Moloney disease in non-human primates through expo- 
sure to a large amount of virus in a very immune 
suppressed animal, 
While this was a major break thorough in terms of 
the level of gone transfer into the primate hemato- 
poietic ceil, it also demonstrates the potential for sig- 
nificant toxicity of wild type murine retroviruses in 
primates, it reinforces the need to carefully assay 
retroviral stocks used for clinical gone therapy proto- 
cols for the presence of replication competent retro- 
virus, it also holds hope that with high enough titer 
replication virus free stocks of retrovirus that adequate 
levels of gone transfer into the hematopoietic stem cell 
of primates and eventually humans can be achieved. 
VI. Current clinical trials of human gone therapy 
The first trials of introducing a therapeutic gone 
were attempted by an American investigator who per- 
formed clinical trials on two patients overseas. These 
experiments were never approved by the United States 
regulatory agencies. The results were reported in 1985 
[96], in these experiments, l0 s nucleated marrow cells 
were transfected with a plasmid vector that contained 
herpes virus thymidine kinase gone and a human /~- 
globin gone. The cells and transfection vector were 
incubated in vitro, and then infused into two patients 
who had received 0.3 Gray external beam irradiation 
delivered to the femur. The investigator was unable to 
detect vector specific sequences before the transplant. 
Between I-2 weeks after the transplant, less than one 
copy of the transfected sequences were detected by 
Southern blot. An occasional higher molecular weight 
species was observed, perhaps indicating integration of 
the sequences. After 10 weeks, there was no evidence 
of the higher molecular weight species of transfected 
DNA, The transfeeted DNA became undetectable af- 
ter three months in one patient and nine months in 
another patient. The change in hemoglobin levels was 
not reported for either patient. No toxicity was ob- 
served in either patient from the procedure. This ex- 
periment illustrated the difficulty in obtaining long 
term retention of the genetic material in the bone 
marrow of humans when there is no selective pressure 
for the maintenance of the introduced sequences. 
The first fully approved human trial using geneti- 
cally altered T lymphocytes was reported in 1990 [2]. 
The investigators used the retrovirus LNL6, with a best 
titer 2.106 CFU/ml ,  to mark tumor infiitr~:ting lym- 
phocytes (TIL) from 5 patients with metastatic 
melanoma. The TIL were exposed to retrovirus con- 
taining tissue culture supernatailts for 2 h or 2 consec- 
utive days. This resulted in the transduction of between 
1-11% of the cells. Drug resistant lymp~locytes all 
showed presence of unrearranged provirus. Interest- 
ingly, the transduced cells did show some changes in 
cell surface phenotype, although a consister~t pattern of 
change was not observed. Transduced cells from 5 of 6 
of the initially reported patients showed ,'eduction in 
killing of K562 and Daudi cells, but 4 of the 6 patients 
transduced cells demonstrated an increase in autolo- 
gous tumor cell killing. After infusion of genetically 
marked TIL, the investigators were able to detect the 
presence of provirus in peripheral blood and occasion.. 
ally in tumor biopsy specimens. There was no addi- 
tional toxicity of the genetically modified TIL above 
toxicity observed with interleukin 2 and unmodified 
TIL. 
The TIL marking trial demonstrated several impor- 
tant points. First, genetically modified cells could be 
given to patients with no more toxicity that of the 
unmodified, ex vivo cultured cells. Second, retroviruses 
could be generated safely and repetitively in large 
enough quantities for human gene therapy. Third~ 
provirus could be used to genetically mark cells in 
humans, which had already been performed in animals. 
This initial safety study paved the way for the first fully 
approved human gene therapy trial, now underway at 
the NIH. 
As of July, 1992, two patients have been treated 
with genetically modified lymphocytes in an attempt to 
ameliorate ADA deficiency [1]. The first patient was 
treated in September, 1990. In this clinical protocol, 
the retroviral vector LASN (essentially LNLb with the 
addition of an ADA cDNA) was used to transduce the 
peripheral blood lymphocytes of a patient. The lym- 
phocytes were ex vivo expanded in the presence of an 
antibody to T3 (OKT3) and interleukin 2. The cells 
were then exposed to the retrovirus, and infused into 
the patient. The first patient, a 4 yr old girl, has 
received a total of 8 doses of genetically modified T 
cells, obtaining up to 25% of normal peripheral blood 
ADA levels (as compared to less then 1% pretreat- 
ment). A second patient, an 11 yr old girl, has received 
11 infusions of genetically modified T cells. The results 
have not yet been reported for this patient. 
The genetically modified T cells in one of the pa- 
tients have a half-life of about 90 days, approximately 
3-4 times that of the ex vivo expanded, unmodified T 
cells. These patients have maintained their current 
regimen of ADA replacement with polyethylene glycol 
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modified adenosine deaminase. In addition, the inves- 
tigators have been able to demonstrate reconstitution 
of isohemaglutinins, diphtheria, and tetnus antibodies. 
These initial very promising results have lead to a 
proposal to genetically modify the hematopoietic stem 
cell of these two patients. 
The Recombinant DNA advisory committee of the 
NIH has recently approved a protocol to genetically 
modify the peripheral blood stem cells of these same 
two patients, and the protocol is awaiting final FDA 
approval. The proposed trial is to harvest peripheral 
blood stem cells, enrich for CD34 positive cells, expose 
the CD34 positive cells to a recombinant retrovirus 
encoding for adenosine deaminase in the presence of 
growth factors (interleukin 3, interleukin 6, and stem 
cell factor), and reinfuse the genetically modified cells 
back into the patients. This trial stands a reasonable 
chance of success because even at lower gene transfer 
levels obtainable into the heraatopoietic stem cell of 
primates, there is a selective pressure for the geneti- 
cally modified cells in patients with ADA deficiency. In 
addition, the patients need not be subjected to pre- 
transplant transplant myeloablation, and so the risk of 
the procedure is almost identical to that of infusing 
transduced T cells. This should provide an exciting 
starting ground for many human trials to come in the 
yt~ars ahead. 
Viii. Concluding remarks 
Hematopoietic stem cell gene therapy offers much 
pronlise for the cure of diseases. In adenosine deami- 
nase deficiency, clinical trials of human hematopoietic 
stem cell gene transfer are about to commence. The 
advent of clinical trials represent the combined hard 
work of a number of investigators. Gene therapy trials 
of this disease have a relatively high chance of success 
and pose little risk to the patient because of the. wide 
range of normal expression of adenosine deaminase 
and the ability to cure patients without performing 
bone marrow transplantation conditioning. While likely 
to be successful, the total clinical impact in health care 
may be small because of the relative rarity of adeno- 
sine deaminase deficiency. 
in contrast, the treatment of the hemoglobinopathies 
(such as sickle cell disease and severe thalessemia) with 
hematopoietic stem cell gene therapy still appears to 
be years away. This relates to the problem,; of achiev- 
ing high enough levels of the recombinant protein 
expressed in the majority oi erythrocytes to provide 
amelioration of the disease. In addition, patients with 
these diseases are at greatly increased risk of increased 
mortality with bone marrow transplantation because of 
their iron overload status and subsequent end organ 
damage. Furthermore, they must be conditioned with 
chemotherapy to engraft the muitipotent hemato- 
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poietic stem cell which gives rise to erythrocytes. Thus, 
there is a great deal of investigation to be performed to 
bring to fruition clinical trials in the hemoglobino- 
pathies. 
These two conditions provide the range of the clini- 
cal problems encountered with genetically modifying 
the hematopoietic stem cell. Adenosine deaminase de- 
ficient patients have a debilitating and lethal disease, 
and provide a selective advantage to genetically modi- 
fied hematopoietic stem cells. Additionally, a wide 
range of expression of the transgene should provide a 
therapeutic benefit. On the other hand, the hemoglo- 
binopathies require a high level of expression of pro- 
tein at a very limited point in erythroid development. 
The patients with the hemoglobinopathies must be 
subjected to a more ris~ transplant because there is 
no selective advantage for normal cell, and they are at 
greater risk of transplant because of their underlying 
disease. Thus, before a clinical trial could commence, 
adequate levels of gone transfer and adequate levels of 
transgene expression would need to be demonstrated. 
For the hemogiobinopathies, neither of these condi- 
tions have been met, and this poses a challenge for 
investigators of hematopoietic stem cell gone therapy 
to overcome, 
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